Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | UDP galactose 4'-epimerase | 0.0396 | 0.9589 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0138 | 0.3039 | 0.3169 |
Echinococcus granulosus | UDP glucose 4 epimerase | 0.0396 | 0.9589 | 1 |
Loa Loa (eye worm) | follicle stimulating hormone receptor | 0.0234 | 0.5469 | 0.5704 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.1047 | 0.1092 |
Echinococcus multilocularis | UDP glucose 4 epimerase | 0.0396 | 0.9589 | 1 |
Brugia malayi | Cytochrome P450 family protein | 0.0023 | 0.0097 | 0.0101 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.1047 | 0.1092 |
Brugia malayi | hypothetical protein | 0.002 | 0.0015 | 0.0016 |
Trichomonas vaginalis | NAD dependent epimerase/dehydratase, putative | 0.0396 | 0.9589 | 1 |
Trypanosoma cruzi | UDP-galactose 4-epimerase | 0.0396 | 0.9589 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0138 | 0.3039 | 0.3169 |
Brugia malayi | hypothetical protein | 0.003 | 0.029 | 0.0302 |
Mycobacterium tuberculosis | Probable fructose-bisphosphate aldolase Fba | 0.0151 | 0.335 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.029 | 0.5 |
Trichomonas vaginalis | UDP-glucose 4-epimerase, putative | 0.0396 | 0.9589 | 1 |
Leishmania major | udp-glc 4-epimerase, putative | 0.0412 | 1 | 1 |
Trichomonas vaginalis | NAD dependent epimerase/dehydratase, putative | 0.0396 | 0.9589 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.029 | 0.5 |
Brugia malayi | UDP galactose 4'-epimerase | 0.0396 | 0.9589 | 1 |
Toxoplasma gondii | UDP-glucose 4-epimerase | 0.0396 | 0.9589 | 1 |
Entamoeba histolytica | UDP-glucose 4-epimerase, putative | 0.0396 | 0.9589 | 1 |
Schistosoma mansoni | UDP-glucose 4-epimerase | 0.0396 | 0.9589 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.1047 | 0.1092 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.1047 | 0.1092 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.0563 | 0.0587 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0138 | 0.3039 | 0.3169 |
Trypanosoma cruzi | UDP-galactose 4-epimerase, putative | 0.0396 | 0.9589 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0023 | 0.0097 | 0.0101 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0138 | 0.3039 | 0.3169 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0138 | 0.3039 | 0.3169 |
Brugia malayi | follicle stimulating hormone receptor | 0.0234 | 0.5469 | 0.5704 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0138 | 0.3039 | 0.3169 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.0563 | 0.0587 |
Mycobacterium leprae | Probable fructose bisphosphate aldolase Fba | 0.0151 | 0.335 | 0.5 |
Mycobacterium ulcerans | fructose-bisphosphate aldolase | 0.0151 | 0.335 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0138 | 0.3039 | 0.3169 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.029 | 0.0302 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0138 | 0.3039 | 0.3169 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.0563 | 0.0587 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.029 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0138 | 0.3039 | 0.3169 |
Treponema pallidum | fructose-bisphosphate aldolase | 0.0308 | 0.7365 | 0.5 |
Trypanosoma brucei | UDP-galactose 4-epimerase | 0.0412 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.7943 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 3.1623 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 15.8489 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PubChem BioAssay. qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.